• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Small Innovators & Niche CROs

    Focus on Science

    Rapid and Data Rich Chromatographic Method Development

    Preparing Your Post Pandemic Talent Strategy

    How Modern Near-Infrared Came to Be
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    AGC Biologics Appoints Jun Takami GM of Chiba Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Ascendia Pharmaceuticals Poised for Expansion

    Bora Pharmaceuticals Adds Roller Compaction Capabilities

    Alkermes, Merck Enter Clinical Trial and Supply Agreement

    Sterling Pharma Solutions Acquires ADC Biotechnology

    Moderna, Catalent Enter Long-Term Strategic Vax Pact
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Cryoport Acquires Critical Transport Solutions Australia

    PharmParts – This Makes Sense!

    Securing Your API Supply Chain: Three Keys to Success

    Enteris BioPharma: Custom Solutions – From Bench to Market

    The Benefits of Outsourcing Cold Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ

    Ascendia Pharmaceuticals Poised for Expansion

    Merck KGaA Selects PRA’s Remote Patient Monitoring Platform

    Agilex Biolabs Acquires TetraQ for APAC Expansion Plans

    Alkermes, Merck Enter Clinical Trial and Supply Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    What Will Change at FDA for 2021?

    RBQM Comes of Age: COVID as a Catalyst for Change

    Post-Pandemic Regulations

    Enteris BioPharma: Custom Solutions – From Bench to Market

    Metrics Contract Services Completes Russian Regulatory Inspection
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Quotient Sciences

    Almac Group

    Aphena Pharma Solutions

    PCI Pharma Services

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Baxter BioPharma Solutions

    Almac Group

    Aphena Pharma Solutions

    Alcami

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Developing Faster-to-Clinic Formulations

    When standard formulation strategies fail, is there a fast path to clinic for hard-to-formulate therapeutics?

    Developing Faster-to-Clinic Formulations
    Related CONTENT
    • Vetio Animal Health
    • Eurofins, Astellas Sign Outsourcing Agreement
    • Astex to Install Thermo Fisher's Glacios Cryo-TEM
    • Recipharm, Hadasit Enter Partnership
    • Q Therapeutics, REPROCELL Form MAGiQ Therapeutics
    Phil Morton, Chief Technology Officer, Albumedix06.12.18
    A  critical objective of any drug development program is to create faster-to-clinic stable formulations. Maximizing the stability of a therapeutic protein, peptide or vaccine is not an easy task. The use of recombinant albumin has the potential to bring valuable yet initially unstable, hard-to-formulate drug candidates to market. By providing improved dose control through protection against non-specific surface adsorption and reduction of unwanted immunogenicity through inhibition of aggregation and prevention of oxidation, recombinant albumin offers drug developers new potential for creating faster-to-clinic biological drugs and vaccines. 

    Drug Development Challenges
    Modern pharmaceuticals are changing. The industry is moving towards more complex molecules, such as antibody drug conjugates, vaccines and cell-based therapies and this presents formulation challenges. Formulation of hard-to-stabilize biologics is not a simple task. Issues can include physical degradations—aggregation/fibrillation, adsorption/depletion, unfolding, solubility/precipitation—and chemical degradations—oxidation, deamidation, truncation/degradation, hydrolysis.

    Manufacturers are confronted with countless challenges during the formulation of novel drug classes. For instance, formulating antibodies to very high concentrations escalates the probability of products undergoing stability issues. Modified peptides and proteins with altered sequences and/or additional non-natural amino acids can also present stability issues. Additionally, highly active potent drugs, such as growth factors and hormones, often require dosing at very low levels, making dose control critical and difficult to achieve.
    Aggregation and depletion of proteins and peptides in drug formulations is a major source of dosage form and storage instability. The presence of aggregates and sub-visible particles also compromises the safety and efficacy of the drug formulations and may lead to a series of problems during manufacturing, handling and post administration. As such the minimization of protein aggregation and chemical degradation is part of a de-risking strategy key to ensuring a smoother “developability” of a biopharmaceutical.

    Standard formulation technologies do not offer the required stabilization capabilities for today’s advanced, complex therapeutics. For instance, lipids present in vaccine and cell-based therapies can be broken-up by standard excipient approaches and using detergents are ineffective. Products that require high concentrations can be limited by viscosity issues and the incidence of multiple issues, such as aggregation and oxidation occurring simultaneously, is common. Excipients that can mitigate multiple issues would bring significant benefits, and this is where the use of albumin in formulation represents a welcome alternative to traditional strategies.

    The Albumin Answer
    Human albumin, the most abundant carrier protein in plasma, constitutes 60% of total plasma protein. In the human body, albumin is responsible for the maintenance of oncotic pressure, plasma pH and the distribution of a variety of endogenous and exogenous ligands. Seventeen disulphide bonds give the albumin molecule excellent stability and resilience to environmental stress. It also contains multiple ionic and hydrophobic binding sites, where chemicals bind and are consequently transported around the body. Albumin is widely used in the manufacture of drug, vaccine, and device products for a range of applications such as formulation, drug delivery, and medical device coating.

    Albumin offers a relatively simple solution to traditional strategies that require multiple stabilizers, or new strategies that require considerable experimentation before the point of formulation can be reached. It readily adsorbs to both hydrophobic and hydrophilic surfaces preventing non-specific adsorption of biopharmaceuticals during manufacture, formulation and storage. By dispersing uniformly in a solution it affords an insulating quality that minimizes physical drug instability and protein-protein interactions. As it has several different binding pockets, albumin can also interact with a diverse range of products and thereby stabilize them. These multiple mechanisms mean that albumin can stabilize products in a variety of situations and stresses.

    Recombinant Albumin In Use
    Although serum derived (human or bovine) albumin has been widely recognized as an effective stabilizer for many years, it has suffered a decline in popularity due to regulatory preference (concerns over blood-borne contaminants) for animal origin-free options. Today, with the availability of recombinant albumin, this is no longer an issue.

    High-quality, animal origin-free recombinant human albumin, approved for use in the manufacture of human therapeutics, acts as an effective versatile stabilizer with the ability to protect challenging drug, cell and vaccine products from aggregation, non-specific adsorption, and oxidation. It enables drug developers to readily formulate otherwise instable drug candidates and to simplify their formulation strategy. As a result, albumin-enabled technology offers a fast, established pathway to the clinic and ultimately to market.

    In use, recombinant albumin protects interferons against oxidation and adsorption, while improving solubility and reducing the potential for aggregation. It contributes low immunogenicity, alleviates any co-aggregation due to increased purity and less contaminating high molecular weight material. Recombinant albumin offers easier handling and improved patient compliance by enabling reformulation from lyophilized to simple liquid formulations and contributes improved stability in both liquid and solid state for vaccine products, improving yields during the process of harvesting and processing viruses for vaccine preparation. It also provides batch-to-batch consistency.

    Conclusion
    Because of its capabilities, albumin-enabled technology can help provide otherwise impossible drug candidates with a fast and clear path to market, paving the way to better health. With wide-ranging applications in the areas of formulation, drug delivery and medical device coating, recombinant albumin has demonstrated proven advantages for challenging peptide and protein formulations, down-stream processing of viral vaccines, stem cell and immunotherapy culturing, sub-unit and viral-vector formulations, biocompatible surface-coating of medical devices, well as cell therapy preservation and formulation. 


    Phil Morton is the Chief Technology Officer heading up Albumedix technology group. He has more than 20 years’ experience in the biopharmaceutical industry within process and product development both in R&D and manufacturing environments. His experience ranges from developing and transferring purification processes, to formulation development and characterization of these processes and products. Phil holds a Ph.D. in Biochemical Engineering from Birmingham University and followed this with post-doctoral studies at Cambridge University.
    Related Searches
    • Dosage
    • antibody drug conjugates
    • it
    • Stability
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Eurofins, Astellas Sign Outsourcing Agreement Eurofins, Astellas Sign Outsourcing Agreement
    Astex to Install Thermo Fisher Astex to Install Thermo Fisher's Glacios Cryo-TEM
    Recipharm, Hadasit Enter Partnership Recipharm, Hadasit Enter Partnership
    Q Therapeutics, REPROCELL Form MAGiQ Therapeutics Q Therapeutics, REPROCELL Form MAGiQ Therapeutics
    Selexis Installs $2M in New Lab Equipment Selexis Installs $2M in New Lab Equipment
    Janssen Janssen's Supply Chain VP Talks Trends
    Helsinn Group, Actelion Pharma Enter Agreement Helsinn Group, Actelion Pharma Enter Agreement
    Abzena Strengthens Specialized Bioassay Offering Abzena Strengthens Specialized Bioassay Offering
    Intec Pharma Partners with LTS for Parkinson Intec Pharma Partners with LTS for Parkinson's
    What to Look for in a Contract Manufacturer What to Look for in a Contract Manufacturer
    Finding Value in Quality Contract Manufacturing Finding Value in Quality Contract Manufacturing
    FDA’s Increased Information Transparency FDA’s Increased Information Transparency
    Pall Launches Biotech Business Unit Pall Launches Biotech Business Unit
    Massive Growth for the Biotechnology Market by 2024 Massive Growth for the Biotechnology Market by 2024

    Related Features

    • Formulation Development
      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      **ADVERTORIAL** Advanced Formulation Development by Design in the Context of Holistic Drug Production

      A strong trend in drug substance and drug product biomanufacturing, as is for formulation, is that of increasing therapeutic complexity.
      Latika Bhonsle-Deeng, Rentschler Biopharma SE, and Konstantin Petropoulos, LEUKOCARE AG 10.14.20

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    • Formulation Development
      Formulation Development Trends

      Formulation Development Trends

      Innovation in formulation development continues to be driven by the need to improve drug bioavailability.
      Torkel Gren, General Manager, Recipharm Pharmaceutical Development AB 04.10.18


    • Formulation Development | Preclinical Outsourcing
      Formulating Candidates  with Bioavailability Issues

      Formulating Candidates with Bioavailability Issues

      To avoid the solubility pitfalls that too often halt a medicines progress from clinic to market, it’s vital to start formulat
      Stephen Tindal, Director - Science and Technology, Catalent 05.09.17

    • Drug Development | Formulation Development
      Formulation Strategies for  Aging Consumers

      Formulation Strategies for Aging Consumers

      Convenience, flavor and novel combinations of ingredients can help offer better product experiences.
      Stephen Tindal, Director, Science and Technology, Catalent Pharma Solutions 03.07.17

    • Drug Development | Formulation Development
      Modeling & Simulation for  Drug Development & Formulation

      Modeling & Simulation for Drug Development & Formulation

      A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.
      Nathan Teuscher and Nikunjkumar Patel , Certara 03.07.17


    • APIs | Clinical Trial Materials | Clinical Trials | Drug Development | Formulation Development
      Choosing Oral Formulations for First-in-man Clinical Trials

      Choosing Oral Formulations for First-in-man Clinical Trials

      Early formulations should be simple, but selecting a simple formulation isn’t as easy as it seems
      Jon Sutch, Senior Manager of Formulation Development, Patheon 10.11.16

    • Biosimilars | Clinical Trials | Formulation Development
      Critical Steps for Biosimilar Assessment

      Critical Steps for Biosimilar Assessment

      Establishing “finger-print like” biosimilarity prior to the clinic
      Fiona Greer, SGS 05.05.16

    • Capsules | Clinical Trials | Excipients | Formulation Development | Serialization
      The Evolution of the ‘One-Stop Shop’  in Clinical Supplies Sourcing

      The Evolution of the ‘One-Stop Shop’ in Clinical Supplies Sourcing

      What does a one-stop shop really mean and is it always best for the client?
      Paul Skultety, Alex McClung, Ted Koontz and Damian Gant, Xcelience, a division of Capsugel Dosage Form Solutions 05.05.16


    • APIs | cGMP Manufacture | Drug Development | Facilities | Formulation Development | Supply Chain

      Newsmakers: Ian Muir

      End-to-End Service
      Tim Wright, Editor 04.05.16

    • Capsules | cGMP Manufacture | Clinical Trials | Drug Development | Drug Discovery | Excipients | Facilities | Formulation Development
      Solid Dispersions

      Solid Dispersions

      A universal formulation strategy for poorly soluble drugs?
      Robert Harris, Juniper Pharma Services 04.05.16

    • Capsules | Chemistry | Extractables and Leachables | Fill/Finish | Formulation Development | Supply Chain

      Newsmakers: Hanns-Christian Mahler

      Head of drug product services talks about Lonza’s new capabilities
      Tim Wright, Editor 03.09.16


    • APIs | Biosimilars | Drug Delivery | Drug Development | Fill/Finish | Formulation Development | Lyophilization | Parenterals | Supply Chain
      Parenteral Outsourcing Trends

      Parenteral Outsourcing Trends

      Contract Pharma asked a roundtable of business leaders from Symbiosis, Grifols, Althea, LSNE and Baxter to discuss key trends in the parenteral dosage development and manufacturing market
      Tim Wright, Editor 03.09.16

    • APIs | Capsules | Chemistry | Drug Delivery | Excipients | Formulation Development | Serialization | Supply Chain
      Solid Dosage Outsourcing Trends

      Solid Dosage Outsourcing Trends

      The market continues to evolve as blockbusters are replaced by more targeted treatments that have unique requirements.
      Tim Wright, Editor 03.09.16

    • APIs | Capsules | Clinical Trials | Drug Delivery | Excipients | Formulation Development
      Developing Palatable Drug Products

      Developing Palatable Drug Products

      A decision framework and guide for CDMOs
      Jeff Worthington and David Tisi, Senopsys LLC 03.09.16

    Trending
    • Sterling Pharma Solutions Acquires ADC Biotechnology
    • Sanofi To Build New $700M Flu Vaccine Facility In Canada
    • Alkermes, Merck Enter Clinical Trial And Supply Agreement
    • Ascendia Pharmaceuticals Poised For Expansion
    • Frontage Expands Capabilities At Its Clinical Site In Secaucus, NJ
    Breaking News
    • Bora Pharmaceuticals Adds Roller Compaction Capabilities
    • Ascendia Pharmaceuticals Poised for Expansion
    • Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    • Merck KGaA Selects PRA’s Remote Patient Monitoring Platform
    • AGC Biologics Appoints Jun Takami GM of Chiba Site
    View Breaking News >
    CURRENT ISSUE

    April 2021

    • Small Innovators & Niche CROs
    • Focus on Science
    • Rapid and Data Rich Chromatographic Method Development
    • Preparing Your Post Pandemic Talent Strategy
    • How Modern Near-Infrared Came to Be
    • Securing Your API Supply Chain: Three Keys to Success
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Kyowa Hakko Launches Heat-Treated Probiotic Strain for Eye Health
    CGA-7 Green Coffee Extract by Vidya Herbs Achieves Self-Affirmed GRAS Status
    Nutritional Complex Evidenced to Reduce Preterm Birth
    Coatings World

    Latest Breaking News From Coatings World

    Barentz Expands Canadian CASE Team
    Shepherd Color Company Opens Sales Office in China
    Chromaflo Technologies Awarded Gold Status CSR Rating by EcoVadis in EMEA
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    CMS Establishes New Payment for Pelvalon’s Eclipse System
    Varian, Google Cloud Partner to Bring Convenience to Cancer Therapy
    Resonetics Leases New Manufacturing Space in Costa Rica
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Frontage Expands Capabilities at its Clinical Site in Secaucus, NJ
    Ascendia Pharmaceuticals Poised for Expansion
    Bora Pharmaceuticals Adds Roller Compaction Capabilities
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Revlon Unveils New Fragrances Featuring Megan Thee Stallion & Sofia Carson
    Henkel Management Board Welcomes Wolfgang König
    Mielle Organics Gets a Major Investment
    Happi

    Latest Breaking News From Happi

    Nature’s Beauty Debuts Vegan Natural Body Care at Walgreens
    Estée Lauder Expands 'Beautiful' Fagrance Collection
    Mushrooms Are Key Ingredients in Beauty & Wellness
    Ink World

    Latest Breaking News From Ink World

    SE-DA Invests in Kornit Presto S
    Kumon North America Adds Speedmaster XL 106 from Heidelberg
    Iron Oxide Pigments Market to Register 4.7% CAGR from 2021 to 2028: GVR
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Dantex elevates Joseph Sanchez to digital business development manager
    Mactac's Kevin Clunie joins TLMI panel
    MacDermid announces two new global sales roles
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Precision Textiles Offers Biodegradable Medical Fabric
    Northshore Launches Megamax Briefs in New Colors
    Essity Acquires Distribution Rights to Sorbact in Australia and New Zealand
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    New Biosealant Could Stabilize Cartilage, Boost Healing After Injury
    Google Executive Joins SeaSpine's Board of Directors
    HSS and LimaCorporate Open Provider-Based 3D Design and Printing Facility
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Tive Multi-sensor Tracker Solo 5G Relies on Sensirion SHT33
    VTT in 2020: Successful Year Despite Globally Challenging Times
    Lux Research: 3D Printing Market to Reach $51 Billion in 2030

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login